Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $4.6 million.

  • RedHill Biopharma's Cash & Equivalents fell 3655.35% to $4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.6 million, marking a year-over-year decrease of 3655.35%. This contributed to the annual value of $4.6 million for FY2024, which is 1709.46% down from last year.
  • Latest data reveals that RedHill Biopharma reported Cash & Equivalents of $4.6 million as of Q2 2025, which was down 3655.35% from $4.6 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Cash & Equivalents peaked at $76.0 million during Q1 2021, and registered a low of $4.6 million during Q4 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $20.0 million (2022), whereas its average is $25.7 million.
  • As far as peak fluctuations go, RedHill Biopharma's Cash & Equivalents soared by 7853.43% in 2021, and later plummeted by 7211.04% in 2023.
  • RedHill Biopharma's Cash & Equivalents (Quarter) stood at $29.5 million in 2021, then crashed by 32.25% to $20.0 million in 2022, then plummeted by 72.11% to $5.6 million in 2023, then decreased by 17.09% to $4.6 million in 2024, then changed by 0.0% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q2 2025, $4.6 million for Q4 2024, and $7.3 million during Q2 2024.